Summary: In a combined mouse and clinical study, the bone-forming agent rhPTH(1-34) reversed the low bone turnover characteristic of type 2 diabetic bone disease and improved bone density more than the antiresorptive alendronate, particularly at the lumbar spine in diabetic postmenopausal women.
PICO Summary
| Element | Detail |
|---|---|
| Population | Diabetic mouse model plus postmenopausal women with osteoporosis, with and without type 2 diabetes; single-centre, open-label clinical trial over 1 year, China. |
| Intervention | Recombinant human parathyroid hormone rhPTH(1-34), an anabolic (bone-forming) agent. |
| Comparison | Alendronate, a standard antiresorptive bisphosphonate. |
| Outcome | Diabetic mice and diabetic osteoporotic patients showed low bone turnover (reduced P1NP, CTX, osteocalcin). rhPTH(1-34) reversed the low turnover and improved bone density and microstructure more than alendronate, with a better lumbar-spine effect in diabetic patients. Notably, alendronate’s lumbar-spine benefit in diabetic patients was even smaller than in non-diabetic osteoporosis. |
Expert Commentary
This is a mechanistically satisfying study that aligns treatment choice with disease biology, which is its main strength. Diabetic bone disease is characteristically a low-turnover state, where bone is fragile despite often normal or high density, and that pathophysiology predicts that piling on an antiresorptive, which further suppresses an already sluggish remodelling system, may help less than an anabolic agent that actively rebuilds bone. The data support exactly that logic across both arms: rhPTH(1-34) reversed the low turnover and outperformed alendronate on density and microstructure, and the telling detail is that alendronate’s lumbar benefit was even weaker in diabetic than in non-diabetic osteoporosis. I would temper this with the study’s limits, an open-label single-centre clinical component paired with an animal model, surrogate endpoints of density and turnover markers rather than fracture reduction, and a one-year horizon. I would also avoid overclaiming on adverse events, since the abstract does not detail them; transient hypercalcaemia and injection-site reactions are recognised class effects of PTH analogues rather than reported trial findings. Can I use this with my patients? Conceptually, yes. It strengthens the rationale for favouring an anabolic agent in diabetic patients with low-turnover osteoporosis, while I await fracture-outcome data before treating this as settled.
References
Li H, Yuan L, Liu P, et al. Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease. Front Endocrinol (Lausanne). 2025;16:1657481. doi:10.3389/fendo.2025.1657481